Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Notes Payables (2022)

Historic Notes Payables for RedHill Biopharma (RDHL) over the last 1 years, with Q4 2022 value amounting to $115.2 million.

  • RedHill Biopharma's Notes Payables changed N/A to $115.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $115.2 million, marking a year-over-year change of. This contributed to the annual value of $115.2 million for FY2022, which is N/A changed from last year.
  • RedHill Biopharma's Notes Payables amounted to $115.2 million in Q4 2022.
  • RedHill Biopharma's Notes Payables' 5-year high stood at $115.2 million during Q4 2022, with a 5-year trough of $115.2 million in Q4 2022.